Loading…
← CockpitCompetitor Analysis › MYGN Myriad Genetics, Inc.Open in the cockpit ↗

Myriad Genetics, Inc.MYGNCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 97
Mkt cap
$530M
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$11.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-33.8 pp
WACC 11.0%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$5.53
1D-0.2%
1W-3.3%
1M-0.2%
3M+71.7%
6M+45.1%
YTD-10.1%
1Y-17.0%
ATR %6.1%
Beta0.55
52w lowhigh31.6% off high

What Myriad Genetics does

Employees: 2,700

Myriad Genetics at a glance

Size Myriad Genetics (MYGN) is a United States Health Care company (Medical Specialties) with a market value of $530M, the 2633rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.53 on 18 Nov 2026.

Performance Over six months the shares gained 45.1%, against -23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 2.6% over the last twelve months (peer median +6.1%); the operating margin is -13.3% (peer median 2.5%).

Valuation It trades at 0.8× enterprise value to sales against a peer median of 3.6× (cheapest of 19).

Capital Return on invested capital runs 33.8 points below its cost of capital (11.0% WACC).

Short interest Short interest is 8.8% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026MYGN 141Peer median 78
Six months, rebased to 100: Myriad Genetics against the median of its 20 peers (local-currency closes).

Myriad Genetics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$804M$824M$838M$753M$678M
Revenue growth—-2%+11%+11%—
Gross profit$519M$577M$585M$474M$435M
EBITDA-$57.9M-$13.6M-$26.0M-$71.4M-$53.9M
Net income-$129M-$366M-$127M-$263M-$112M
Free cash flow-$33.9M-$13.8M-$27.7M-$174M-$152M
Capital expenditure$17.8M$27.4M$29.7M$73.3M$45.3M
Total debt$209M$210M$140M$152M$145M

Quarterly statements and history in the cockpit →

Myriad Genetics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%ZJYLRCEL605369300439NNNN3008693006397979AVR688075603122301235688580MEDXPACB603520300952002932MYGN6-month return →1-month return →
Up and to the right = strong over both horizons. Myriad Genetics is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×50×100×ZJYLRCEL6053693004393008693006397979AVR688075603122688298301235PACB688606MYGNRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Myriad Genetics is the large dot.

Myriad Genetics competitors and peer comparison

How Myriad Genetics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Myriad Genetics against its 20 peers (data as of 18 Nov 2026)
MeasureMYGNPeer medianRank in peer set
1-month return-0.2%-6.7%6th highest of 21
6-month return+45.1%-23.4%4th highest of 21
Distance from 52-week high-31.6%-44.6%6th highest of 21
Revenue growth (TTM)-2.6%+6.1%7th lowest of 21
Operating margin-13.3%2.5%7th lowest of 21
EV / Sales0.8×3.6×cheapest of 19
ROIC minus cost of capital-33.8 pp-2.2 pp2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
AVITA Medical RCELUnited States$529M+290%+17%-34%6.7×n/an/a
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%1.5×6.0%-7.7%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%5.5×15.0%-19.8%
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%3.9×0.4%-13.2%
Shofu 7979.TJapan$510M+32%+9%14%1.6×n/an/a
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%125.0×n/an/a
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%5.4×30.8%-18.6%
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%5.9×n/an/a
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%1.6×n/an/a
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%1.6×n/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%5.3×20.1%+4.2%
medmix MEDX.SWSwitzerland$494M+11%-7%6%1.4×4.5%+5.0%
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%6.7×n/an/a
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%2.2×n/an/a
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%3.3×n/an/a
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%1.3×-6.5%-4.3%

Questions

Which companies are Myriad Genetics's closest peers?
The cockpit's peer set: Jin Medical International (ZJYL), AVITA Medical (RCEL), Zhejiang Gongdong Medical Technology (605369.SS), MedicalSystem Biotechnology (300439.SZ), Anbio Biotechnology (NNNN), Contec Medical Systems (300869.SZ), Guangdong Hybribio Biotech (300639.SZ), Shofu (7979.T).
Is Myriad Genetics expensive compared with its peers?
On ev / sales it trades at 0.8× against a peer median of 3.6×, cheapest of 19 in its peer set.
How has Myriad Genetics stock performed?
Over six months to 18 Nov 2026 the shares returned +45.1% against -23.4% for the median peer; over one year -17.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.